The United States’ food and drug regulator, the Food and Drug Administration (FDA), is reportedly gearing up to implement numerous anticipated rules and guidelines in the upcoming year of 2024. This development, fueled by the election year, is under the backdrop of a legal dispute at the historic US Supreme Court pertaining to the agency’s actions.
Among its comprehensive task list for the forthcoming year, FDA’s objectives include the regulation of laboratory-developed tests, the prohibition of selective tobacco goods, and the implementation of guidelines for medical devices along with artificial intelligence (AI). The agency also intends to take action concerning drug shortages. These endeavors constitute a substantial part the agency’s plans, and as a result, stakeholders are monitoring these initiatives with keen interest moving into the new year.
This wave of activity is coinciding with a case involving the FDA set to be presented before the Supreme Court. The FDA has appealed to the Supreme Court, following a judgment from the Fifth Circuit, whose lengthy decision will be anxiously watched by attorneys and legal experts worldwide.
For more information and further developments, take a look at the full article by Nyah Phengsitthy at Bloomberg Law.